Temozolomide: Realizing the promise and potential

Current Opinion in Oncology

Volumn 15, Issue 6, 2003, Pages 412-418

  Nagasubramanian, R ^a   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Brain tumor; Clinical trial; Methylating agent; Resistance

Indexed keywords

CARMUSTINE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; IRINOTECAN; NITROSOUREA DERIVATIVE; PROCARBAZINE; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BRAIN CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG SENSITIVITY; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOMA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; VOMITING;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS;

EID: 0742322160     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200311000-00002     Document Type: Review

References (53)

1. Greenlee RT, Murray T, Bolden S, et al.: Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7-33.
2. Stevens MF, Hickman JA, Stone R, et al.: Antitumor imidazotetrazines, 1: synthesis and chemistry of 8-carbamoyl-3-(2-chloroetnyl)imidazo[5, 1-d]-1,2,3,5-tetrazin-4(3 H)-one, a novel broad-spectrum antitumor agent. J Med Chem 1984, 27:196-201.
3. Newlands ES, Blackledge GR, Slack JA, et al.: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992, 65:287-291.
4. Stevens MF, Hickman JA, Langdon SP, et al.: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5, 1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987, 47:5846-5852.
5. Denny BJ, Wheelhouse RT, Stevens MF, et al.: NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry (Mosc) 1994, 33:9045-9051.
6. Modrich P, Lahue R: Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem 1996, 65:101 -133.
7. Hickman MJ, Samson LD: Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci U S A 1999, 96:10764-10769.
8. Brada M, Judson I, Beale P, et al.: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999, 81:1022-1030.
9. Stupp R, Ostermann S, Leyvraz S, et al.: Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc ASCO 2001, 20:59a.
10. Yung WK, Albright RE, Olson J, et al.: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:588-593.
11. Yung WK, Prados MD, Yaya-Tur R, et al.: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group [published correction appears in J Clin Oncol 1999, 17:3693]. J Clin Oncol 1999, 17:2762-2771.
12. 2/d), which, by producing higher peak levels and systemic exposure, may have accounted for the increased toxicity compared with adult studies. This study raises the question whether response rates in children with high-grade gliomas, which are poorer than response rates of adults, are a result of inherent biologic differences causing resistance to temozolomide.
13. Brock CS, Newlands ES, Wedge SR, et al.: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998, 58:4363-4367.
14. Bower M, Newlands ES, Bleehen NM, et al.: Multicentre CRC phase Il trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997, 40:484-488.
15. Newlands ES, O'Reilly SM, Glaser MG, et al.: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996, 32A:2236-2241.
16. Osoba D, Brada M, Yung WK, et al.: Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 2000, 18:1481-1491.
17. Osoba D, Brada M, Yung WK, et al.: Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 2000, 36:1788-1795.
18. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al.: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide [comment]. J Clin Oncol 2002, 20:1375-1382.
19. Gilbert MR, Friedman HS, Kuttesch JF, et al.: A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol 2002, 4:261-267.
20. Quinn JA, Reardon DA, Friedman AH, et al.: Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003, 21:646-651. Encouraging results were seen in patients with low-grade glioma treated with temozolomide. This study demonstrates toxicity in only six of 46 patients and a 12-month PFS of 76%. A large randomized trial in this disease site is warranted
21. van den Bent MJ, Taphoorn MJ, Brandes AA, et al.: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003, 21:2525-2528.
22. Kuo DJ, Weiner HL, Wisoff J, et al: Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J Pediatr Hematol Oncol 2003, 25:372-378. Although retrospective, this study compared the efficacy and toxicity of temozolomide administered as a 5-day regimen or low-dose 42-day regimen in children with progressive low-grade gliomas. With a median follow-up of 21.5 months, the favorable safety profile of temozolomide on the protracted schedule was demonstrated. Nevertheless, all four of the patients with progressive disease were on the 42-day regimen. Despite the small number of patients and short follow-up, there was a significant response rate to temozolomide, obviating the need for further chemotherapy or radiotherapy in eight of the 13 patients.
23. Plowman J, Waud WR, Koutsoukos AD, et al.: Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 1994, 54:3793-3799.
24. Newlands ES, Foster T, Zaknoen S: Phase I study of temozolomide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer 2003, 89:248-251.
25. Schold SC Jr, Kuhn JG, Chang SM, et al.: A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study [published correction appears in Neuro-oncol 2001, 3:123]. Neuro-oncol 2000, 2:34-39.
26. Houghton PJ, Stewart CF, Cheshire PJ, et al.: Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 2000, 6:4110-4118.
27. Okamoto R, Takano H, Okamura T, et al.: O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res 2002, 93:93-102.
28. Pourquier P, Waltman JL, Urasaki Y, et al.: Topoisomerase I-mediated cytotoxicity of N-methyl-N′-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res 2001, 61:53-58.
29. Jones SF, Gian VG, Greco FA, et al.: Phase I trial of irinotecan and temozolomide in patients with solid tumors. Oncology (Huntingt) 2003, 17:41-45.
30. Korones DN, Benita-Weiss M, Coyle TE, et al.: Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 2003, 97:1963-1968.
31. Wedge SR, Porteous JK, Glaser MG, et al.: In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 1997, 8:92-97.
32. Middleton MR, Grob JJ, Aaronson N, et al.: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma [comment; published correction appears in J Clin Oncol 2000, 18:2351]. J Clin Oncol 2000, 18:158-166.
33. Bedikian AY, Papadopoulos N, Plager C, et al.: Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res 2003, 13:303-306.
34. Paul MJ, Summers Y, Calvert AH, et al.: Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002, 12:175-178.
35. Agarwala SS, Kirkwood JM: Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Cancer 2003, 97:121-127.
36. Danson S, Lorigan P, Arance A, et al.: Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003, 21:2551-2557.
37. Dziadziuszko R, Ardizzoni A, Postmus PE, et al.: Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases: a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003, 39:1271-1276.
38. Ebert BL, Niemierko E, Shaffer K, et al.: Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist 2003, 8:69-75.
39. Pegg AE, Dolan ME, Moschel RC: Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995, 51:167-223.
40. Liu L, Markowitz S, Gerson SL: Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 1996, 56:5375-5379.
41. Dolan ME, McRae BL, Ferries-Rowe E, et al.: O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clin Cancer Res 1999, 5:2059-2064.
42. Pagani E, Pepponi R, Fuggetta MP, et al.: DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system. J Chemother 2003, 15:173-183.
43. Tentori L, Graziani G, Gilberti S, et al.: Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia 1995, 9:1888-1895.
44. 6-benzylguanine can be used to inactivate AGT and increase the sensitivity of cells to temozolomide. These studies confirm previous studies demonstrating MMR and AGT as resistant mechanisms to temozolomide.
45. Friedman HS, McLendon RE, Kerby T, et al.: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998, 16:3851-3857.
46. Dolan ME, Moschel RC, Pegg AE: Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A 1990, 87:5368-5372.
47. Dolan ME, Mitchell RB, Mummert C, et al.: Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 1991, 51:3367-3372.
48. Friedman HS, Kokkinakis DM, Pluda J, et al.: Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 1998, 16:3570-3575.
49. Vaish M, Mittal B: DNA mismatch repair, microsatellite instability and cancer. Indian J Exp Biol 2002, 40:989-994.
50. Trojan J, Zeuzem S, Randolph A, et al.: Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology 2002, 122:211-219.
51. Plumb JA, Strathdee G, Sludden J, et al.: Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000, 60:6039-6044.
52. Tolcher AW, Gerson SL, Denis L, et al.: Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003, 88:1004-1011.
53. Spiro TP, Liu L, Majka S, et al.: Temozolomide: the effect of once-and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2001, 7:2309-2317.